Digoxin Tablets, USP 62.5 mcg (0.0625 mg), 100-count bottles, Rx Only, Manufactured by: Novitium ...
FDA Drug Recall #D-0443-2024 — Class III — March 25, 2024
Recall Summary
| Recall Number | D-0443-2024 |
| Classification | Class III — Low risk |
| Date Initiated | March 25, 2024 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Novitium Pharma LLC |
| Location | East Windsor, NJ |
| Product Type | Drugs |
| Quantity | 1,003 bottles |
Product Description
Digoxin Tablets, USP 62.5 mcg (0.0625 mg), 100-count bottles, Rx Only, Manufactured by: Novitium Pharma LLC, 70 Lake Drive, East Windsor, New Jersey 08520, NDC 70954-200-10
Reason for Recall
Failed Impurities/Degradation Specifications
Distribution Pattern
U.S. Nationwide
Lot / Code Information
Lot M23011A; Exp. 12/2024
Other Recalls from Novitium Pharma LLC
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0389-2024 | Class III | Digoxin Tablets, USP 125mcg, (0.125 mg), 1000-c... | Mar 4, 2024 |
| D-0311-2020 | Class II | Novitium Pharma Ranitidine Capsules 150 mg 500 ... | Oct 25, 2019 |
| D-0310-2020 | Class II | Novitium Pharma Ranitidine Capsules 150 mg 60 c... | Oct 25, 2019 |
| D-0312-2020 | Class II | Novitium Pharma Ranitidine Capsules 300 mg 30 c... | Oct 25, 2019 |
| D-0313-2020 | Class II | Novitium Pharma Ranitidine Capsules 300 mg 100 ... | Oct 25, 2019 |
Frequently Asked Questions
Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.